Sudair Pharma was honored to receive His Excellency the Minister of Industry and Mineral Resources during an official visit to the Sudair Industrial Complex, where he laid the foundation stone for the company’s new insulin manufacturing facility.
This milestone project reflects the Kingdom’s commitment to expanding local pharmaceutical production, strengthening medical security, and supporting the objectives of Saudi Vision 2030 through advanced, high-value manufacturing.
A Strategic National Project
During the ceremony, His Excellency reviewed the facility’s development plans and the technologies that will be integrated into the insulin production lines.
The project marks a major step forward in:
Localizing insulin manufacturing
Strengthening the national pharmaceutical supply chain
Reducing dependency on imported essential medications
Building sustainable, long-term industrial capabilities
The Minister emphasized the importance of expanding local production of vital medicines and highlighted Sudair Pharma’s growing role in supporting national healthcare priorities.
Tour of the Sudair Industrial Complex
The visit also included a detailed tour of the industrial complex, where His Excellency was briefed on:
Sudair Pharma’s current advanced manufacturing capacity
Ongoing research and development programs
Expansion plans aligned with international pharmaceutical standards
National workforce development initiatives
The tour showcased the company’s readiness to host a state-of-the-art insulin facility equipped with high-precision and globally compliant production systems.
Supporting Vision 2030 National Industrial Priorities
The foundation stone ceremony reaffirms Sudair Pharma’s commitment to:
Contributing to the Kingdom’s pharmaceutical industrialization
Enhancing health system resilience
Developing specialized manufacturing capabilities
Empowering national talent across critical scientific and technical fields
Sudair Pharma continues to build its position as a key enabler of national industrial transformation and a strategic partner in strengthening the Kingdom’s drug security.
